- Home
- TARS vs KNSA Comparison
TARS vs KNSA Comparison
Compare TARS & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- KNSA
- Stock Information
- Founded
- TARS 2016
- KNSA 2015
- Country
- TARS United States
- KNSA United Kingdom
- Employees
- TARS N/A
- KNSA N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- TARS Health Care
- KNSA Health Care
- Exchange
- TARS Nasdaq
- KNSA Nasdaq
- Market Cap
- TARS 1.8B
- KNSA 1.7B
- IPO Year
- TARS 2020
- KNSA 2018
- Fundamental
- Price
- TARS $53.26
- KNSA $20.49
- Analyst Decision
- TARS Strong Buy
- KNSA Strong Buy
- Analyst Count
- TARS 5
- KNSA 5
- Target Price
- TARS $54.20
- KNSA $36.60
- AVG Volume (30 Days)
- TARS 469.2K
- KNSA 250.8K
- Earning Date
- TARS 11-13-2024
- KNSA 10-29-2024
- Dividend Yield
- TARS N/A
- KNSA N/A
- EPS Growth
- TARS N/A
- KNSA N/A
- EPS
- TARS N/A
- KNSA N/A
- Revenue
- TARS $129,621,000.00
- KNSA $384,098,000.00
- Revenue This Year
- TARS $895.24
- KNSA $60.05
- Revenue Next Year
- TARS $73.78
- KNSA $36.32
- P/E Ratio
- TARS N/A
- KNSA N/A
- Revenue Growth
- TARS 801.96
- KNSA 54.41
- 52 Week Low
- TARS $18.84
- KNSA $16.56
- 52 Week High
- TARS $54.44
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- TARS 64.67
- KNSA 37.25
- Support Level
- TARS $48.45
- KNSA $19.86
- Resistance Level
- TARS $53.85
- KNSA $20.92
- Average True Range (ATR)
- TARS 2.40
- KNSA 0.67
- MACD
- TARS -0.14
- KNSA -0.01
- Stochastic Oscillator
- TARS 80.30
- KNSA 24.05
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.